Company's MelaFind® Application
to Receive Expedited FDA Review

NASDAQ: MELA

Simular to Dendreon Corp. (Nasdaq: DNDN) 2 years ago, MELA stock price may immediately jump 200% to 500% upon FDA Advisory Board approval… let alone final FDA approval. Get up to speed on ElectroOptical Sciences (www.eo-sciences.com), be sure to follow them closely and consider greater accommulation on price pullbacks.

Here's their last news release from mid-February…

Company to File PMA Application With FDA; Largest Prospective Clinical Study Conducted in Melanoma Detection

IRVINGTON, NY 02/13/09 -- Electro-Optical Sciences, Inc. (EOS) (NASDAQ: MELA) announces positive top-line results of its pivotal trial of MelaFind, a non-invasive, point-of-care instrument to assist in the early detection of melanoma, the deadliest form of skin cancer. The blinded study, conducted at seven centers across the US, included 1,831 pigmented skin lesions from 1,383 patients, making this the largest prospective study ever conducted in melanoma detection. EOS is working to complete its Pre-Market Approval (PMA) application and expects to file it with the US Food and Drug Administration (FDA) shortly.

“MelaFind appears to be an excellent tool to help detect melanoma at the earliest, most treatable stage," said Gary D. Monheit, MD, Associate Clinical Professor of Dermatology at the University of Alabama in Birmingham and the lead investigator for the MelaFind pivotal trial. "With no cure for late stage melanoma, early detection is our best defense against this cancer, which has reached epidemic proportions.”

Prior to the start of the study, EOS and the FDA entered into a binding protocol agreement to stipulate the sensitivity and specificity endpoints that should be used to determine the safety and effectiveness of MelaFind.

Outstanding Shares: 17.6 million
Market cap: $75 million

FAST QUOTE ON MELA

As always, do your own due diligence to invest with confidence.

the OTC Money Group